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To determine whether a multihospital Clostridium dif-
ﬁ  cile outbreak was associated with epidemic strains and 
whether use of particular ﬂ  uoroquinolones was associated 
with increased infection rates, we cultured feces from C. 
difﬁ  cile–infected patients. Use of ﬂ  uoroquionolones  with 
enhanced antianaerobic activity was not associated with 
increased infection rates.
R
ecent outbreaks of Clostridium difﬁ  cile infection have 
been attributed to the emergence of an epidemic strain 
characterized as North American pulsed-ﬁ  eld gel electro-
phoresis type 1 (NAP1) or restriction endonuclease assay 
group BI (1,2). Fluoroquinolone resistance is a hallmark of 
epidemic C. difﬁ  cile isolates (1), and ﬂ  uoroquinolone use 
has been associated with C. difﬁ  cile infection (2–9). Be-
cause the C-8 methoxy ﬂ  uoroquinolones gatiﬂ  oxacin and 
moxiﬂ  oxacin have enhanced antianaerobic activity, they 
might promote C. difﬁ  cile infection to a greater degree than 
ciproﬂ  oxacin and levoﬂ  oxacin (10). In 3 studies, substitu-
tion of gatiﬂ  oxacin or moxiﬂ  oxacin for levoﬂ  oxacin was 
associated with an increase in C. difﬁ  cile infection (6,8,9); 
in 2 of the 3 studies, a formulary change back to levoﬂ  oxa-
cin was associated with reduced C. difﬁ  cile infection (6,9). 
However, ciproﬂ  oxacin and levoﬂ  oxacin also have been 
associated with C. difﬁ  cile infection (2–5,7).
Beginning in 2002, outbreaks of C. difﬁ  cile infection 
occurred in several hospitals in the Cleveland, Ohio, USA, 
area. In response, the Ohio Department of Health (ODH) 
made C. difﬁ  cile infection a reportable disease in 2006. One 
objective of the current study was to examine the magni-
tude of the outbreaks in Cuyahoga County, which compris-
es Cleveland and the surrounding area, and to determine 
whether the outbreaks were associated with epidemic BI/
NAP1strains. A second objective was to examine whether 
use of gatiﬂ   oxacin and/or moxiﬂ   oxacin was associated 
with increased rates of C. difﬁ  cile infection in healthcare 
facilities and to assess whether outbreaks correlated with 
formulary changes in ﬂ  uoroquinolones. 
The Study
We used the ODH website (www.odh.state.oh.us) to 
obtain rates (cases/10,000 patient-days) of initial C. dif-
ﬁ  cile infections during January–December 2006 for the 22 
hospitals in Cuyahoga County. All healthcare facilities in 
Ohio were required to submit C. difﬁ  cile infection rates by 
using a standardized method of reporting. An initial case 
was deﬁ  ned as a ﬁ  rst positive laboratory diagnostic test for 
C. difﬁ  cile, pseudomembranes on endoscopy, or conﬁ  rma-
tory histologic features from surgical or autopsy specimen. 
An infection that occurred >6 months after a previous in-
fection was classiﬁ  ed as an initial infection.
For a subset of 5 hospitals, up to 20 consecutive stool 
samples from individual patients with C. difﬁ  cile infection 
were cultured for C. difﬁ  cile (11). C. difﬁ  cile isolates were 
tested for in vitro cytotoxin production and moxiﬂ  oxacin 
susceptibility and analyzed for binary toxin gene cdtB and 
partial deletions of the tcdC gene (11–13). Molecular typ-
ing was performed by using PCR ribotyping (11). The 5 
hospitals were 1 community hospital, 3 tertiary care facili-
ties, and 1 Veterans Affairs hospital. Three of the hospitals 
had experienced large outbreaks of C. difﬁ  cile infection in 
2002–2003 (i.e., their C. difﬁ  cile incidence doubled and 
their peak incidence was >20 cases per 1,000 discharges); 
the other 2 reported an increase in the proportion of cases 
that were fulminant. The infection control departments of 
each institution provided information about C. difﬁ  cile in-
fection rates, ﬂ  uoroquinolones on formulary, and infection 
control measures for C. difﬁ  cile during January 2000–De-
cember 2006.
Rates of C. difﬁ  cile infection for 2006 were compared 
among hospitals with moxiﬂ  oxacin or gatiﬂ  oxacin versus 
those with levoﬂ  oxacin on formulary as primarily  ﬂ  uoro-
quinolones used to treat respiratory infections. In addition, 
for 2 hospitals in the molecular typing analysis that had 
a formulary change from 1 respiratory ﬂ  uoroquinolone 
to another, we used Poisson analysis to compare rates of 
C. difﬁ  cile infection during the 12 months before and af-
ter the formulary change, with a lag of 1 month after the 
change. We analyzed data using SPSS statistical software 
version 10.0 (SPSS Inc., Chicago, IL, USA) and STATA 
9.1 (StataCorp, College Station, TX, USA).
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DOI: 10.3201/eid1605.071606For the 18 adult acute-care hospitals and 4 long-term 
acute-care (LTAC) facilities in Cuyahoga County, the me-
dian C. difﬁ  cile infection rate in 2006 was 7.3 (range 4.2–
63.1 cases/10,000 patient-days). The highest rates were 
observed in 2 LTAC facilities. Six facilities (3 acute-care 
hospitals and 3 LTACs) had higher C. difﬁ  cile infection 
rates than did each of the 5 hospitals in the molecular typ-
ing analysis. 
A total of 64 toxigenic C. difﬁ  cile isolates were cultured 
from feces samples obtained from 5 hospitals. Features of 
42 (66%) isolates were consistent with epidemic BI/NAP1 
strains (range 55%–83% for each facility), including am-
pliﬁ  cation of the binary toxin gene cdtB and partial dele-
tions in tcdC and resistance to moxiﬂ  oxacin (MICs >32 
μg/mL). By PCR ribotyping, we observed a characteristic 
banding pattern for isolates with features of the epidemic 
strain; 6 isolates with this banding pattern were conﬁ  rmed 
as BI strains in the laboratory of D.G.
Of the 22 facilities, 8 used moxiﬂ  oxacin as the primary 
respiratory ﬂ  uoroquinolone, 13 used levoﬂ  oxacin, and 1 
did not have a respiratory ﬂ  uoroquinolone on formulary. 
The C. difﬁ  cile infection rate did not differ between facili-
ties with levoﬂ  oxacin (8.5 cases/10,000 patient-days, 95% 
conﬁ  dence interval [CI] 7.8–9.3) and moxiﬂ  oxacin (8.5 
cases/10,000 patient-days, 95% CI 7.8–9.2) on formulary 
(p = 1) (Table). The facility that did not have a respiratory 
ﬂ  uoroquinolone on formulary had a lower rate of C. dif-
ﬁ  cile infection than the median rates for facilities that used 
levoﬂ   oxacin or moxiﬂ   oxacin. However, 8 facilities had 
lower C. difﬁ  cile infection rates than did this institution.
Two of the 5 hospitals in the molecular typing analysis 
changed their formulary ﬂ  uoroquinolones during the study 
period (Figure). Both hospitals made formulary changes 
from levoﬂ  oxacin to gatiﬂ  oxacin; however, the increase in 
C. difﬁ  cile infection rates preceded the formulary change 
in each hospital. C. difﬁ  cile infection rates did not differ 
signiﬁ  cantly in the 12 months before and after the change 
from levoﬂ  oxacin to gatiﬂ  oxacin (relative risk [RR] 1.0, 
95% CI 0.97–0.86; p = 0.973). For hospital 2 (Figure, 
panel B), a subsequent formulary change from gatiﬂ  oxa-
cin to levoﬂ  oxacin was associated with a reduction in C. 
difﬁ  cile infection (RR 0.59, 95% CI 0.51–0.70; p<0.001); 
an intervention to improve environmental cleaning with a 
10% bleach solution occurred at the time of the formulary 
change.
Conclusions
Our ﬁ  ndings provide further evidence that emergence 
of epidemic NAP1/BI strains in a geographic region may 
be associated with large multihospital outbreaks of C. dif-
ﬁ  cile infection. Before the ODH decision to require man-
datory reporting, many area hospitals were either not col-
lecting surveillance data about C. difﬁ  cile infection or were 
reluctant to share their rates. Therefore, we believe that 
mandatory public reporting of C. difﬁ  cile infection rates 
provided a valuable tool to examine the full magnitude of 
the outbreaks and an incentive for hospitals with high rates 
to increase efforts to control infection. One area hospital re-
cently reported that the ODH database underestimated the 
incidence of C. difﬁ  cile infection (14), but this observation 
does not affect our conclusions because all facilities used 
the same surveillance deﬁ  nitions. Our ﬁ  ndings do not sup-
port the hypothesis that use of moxiﬂ  oxacin or gatiﬂ  oxacin 
is associated with higher rates of C. difﬁ  cile infection than 
is use of levoﬂ  oxacin or ciproﬂ  oxacin. 
Our analysis of formulary ﬂ  uoroquinolones  and  C. 
difﬁ  cile infection has several limitations. First, data on the 
amount of the ﬂ  uoroquinolones used in the hospitals were 
not available. Second, analysis of hospital formularies does 
not account for the effects of ﬂ  uoroquinolones used in long-
term care facilities and among outpatients. Third, we did 
not assess confounding factors, such as use of other classes 
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Table. Clostridium difficile infection rates and healthcare facility characteristics according to respiratory fluoroquinolone on formulary, 
Cleveland, Ohio, USA, 2006* 
Characteristic Levofloxacin Moxifloxacin Neither† Total
No. hospitals  13 8 1 22
No. beds, median (IQR)  232 (108–371)  361 (217–565)  1,008  316 (125–424) 
Type of facility 
 Tertiary  care  0 2 1 3
 Acute  care  9 6 0 15
 Long-term  acute  care  4 0 0 4
Hospital system 
 System  1  1 5 0 6
 System  2  11 0 1 12
 Neither  1 3 0 4
No. cases of C. difficile infection 494 569 206 1,269 
Patient-days 580,893  666,719  293,833  1,541,445 
Rate of C. difficile infection/10,000 patient-days, median (IQR)  8.5 (7.8–9.3)  8.5 (7.8–9.2)  7.0 (6.1–8.0)  8.2 (7.8–8.7) 
*IQR, interquartile range. 
†Ciprofloxacin on formulary but no respiratory fluoroquinolone on formulary. Multihospital C. difﬁ  cile Outbreak
of antimicrobial drugs and differing patient populations. 
Finally, studies that evaluate group-level effects may not 
reﬂ  ect the biological effects at the individual-patient level. 
Additional studies are needed to evaluate the risk for C. dif-
ﬁ  cile infection associated with different ﬂ  uoroquinolones.
This study was supported by an Advanced Research Career 
Development Award from the Department of Veterans Affairs to 
C.J.D. Restriction endonuclease assay typing was provided by 
Susan Sambol under a Department of Veterans Affairs Research 
Service grant to D.N.G. 
Dr Jump is an infectious diseases fellow at University Hos-
pitals in Cleveland, Ohio. Her research interests include intestinal 
immunology and C. difﬁ  cile.
References 
  1.   McDonald LC, Killgore GE, Thompson A, Owens RC, Kazakova 
SV, Sambol SP, et al. An epidemic, toxin gene–variant strain of 
Clostridium difﬁ  cile. N Engl J Med. 2005;353:2433–41. DOI: 
10.1056/NEJMoa051590
  2.   Loo VG, Poirier L, Miller MA, Oughton M, Libman MD, Michaud 
S, et al. A predominantly clonal multi-institutional outbreak of 
Clostridium difﬁ  cile–associated diarrhea with high morbidity and 
mortality. N Engl J Med. 2005;353:2442–9. DOI: 10.1056/NEJ-
Moa051639
  3.   Muto CA, Pokrywka M, Shutt K, Mendelsohn AB, Nouri K, Posey 
K, et al. A large outbreak of Clostridium difﬁ  cile–associated disease 
with an unexpected proportion of deaths and colectomies at a teach-
ing hospital following increased ﬂ  uoroquinolone use. Infect Control 
Hosp Epidemiol. 2005;26:273–80. DOI: 10.1086/502539
  4.   Yip C, Loeb M, Salama S, Moss L, Olde J. Quinolone use as a risk 
factor for nosocomial Clostridium difﬁ  cile–associated diarrhea. Infect 
Control Hosp Epidemiol. 2001;22:572–5. DOI: 10.1086/501954
  5.   McCusker ME, Harris AD, Perencevich E, Roghmann MC. Fluoro-
quinolone use and Clostridium difﬁ  cile–associated diarrhea. Emerg 
Infect Dis. 2003;9:730–3.
  6.   Gaynes R, Rimland D, Killum E, Lowery K, Johnson TM, Kilg-
ore G, et al. Outbreak of Clostridium difﬁ  cile infection in a long-
term care facility: association with gatiﬂ  oxacin use. Clin Infect Dis. 
2004;28:640–5. DOI: 10.1086/381551
  7.   Pepin J, Saheb N, Coulombe M, Alary ME, Corriveau MP, Authier 
S, et al. Emergence of ﬂ  uoroquinolones as the predominant risk fac-
tor for Clostridium difﬁ  cile–associated diarrhea: a cohort study dur-
ing an epidemic in Quebec. Clin Infect Dis. 2005;41:1254–60. DOI: 
10.1086/496986
  8.   Biller P, Shank B, Lind L, Brennan M, Tkatch L, Killgore G, et 
al. Moxiﬂ  oxacin therapy as a risk factor for Clostridium difﬁ  cile–
associated disease during an outbreak: attempts to control a new 
epidemic strain. Infect Control Hosp Epidemiol. 2007;28:198–201. 
DOI: 10.1086/511789
  9.   von Baum H, Sigge A, Bommer M, Kern WV, Marre R, Dohner H, et 
al. Moxiﬂ  oxacin prophylaxis in neutropenic patients. J Antimicrob 
Chemother. 2007;58:891–4. DOI: 10.1093/jac/dkl320
10.    Adams DA, Riggs MM, Donskey CJ. Effect of ﬂ  uoroquinolone 
treatment on growth of and toxin production by epidemic and non-
epidemic Clostridium difﬁ  cile strains in the cecal contents of mice. 
Antimicrob Agents Chemother. 2007;51:2674–8. DOI: 10.1128/
AAC.01582-06
11.   Al-Nassir W, Riggs MM, Bobulsky G, Donskey CJ. A comparison of 
clinical and microbiological response to therapy of Clostridium dif-
ﬁ  cile infection with metronidazole versus vancomycin. Clin Infect 
Dis. 2008;47:56–62. DOI: 10.1086/588293
12.   Terhes G, Urban E, Soki J, Hamid KA, Nagy E. Community-ac-
quired Clostridium difﬁ  cile diarrhea caused by binary toxin, toxin 
A, and toxin B gene-positive isolates in Hungary. J Clin Microbiol. 
2004;42:4316–8. DOI: 10.1128/JCM.42.9.4316-4318.2004
13.   Spigaglia P, Mastrantonio P. Molecular analysis of the pathogenicity 
locus and polymorphism in the putative negative regulator of toxin 
production (TcdC) among Clostridium difﬁ  cile isolates. J Clin Mi-
crobiol. 2002;40:3470–5. DOI: 10.1128/JCM.40.9.3470-3475.2002
14.   Fraser T, Fatica C, Gordon SM. Public reporting of Clostridium 
difﬁ  cile associated diarrhea (CDAD): in-house vs. mandated deﬁ  ni-
tions. In: Abstracts of the 17th Annual Scientiﬁ  c Meeting of The 
Society for Healthcare Epidemiology of America; Baltimore, Mary-
land; 2007 April 14–17; Abstract 168. Arlington (VA): Society for 
Healthcare Epidemiology of America; 2007.
Address for correspondence: Curtis J. Donskey, Infectious Diseases 
Section, Cleveland Veterans Affairs Medical Center, 10701 East Blvd, 
Cleveland, OH 44106, USA; email: curtisd123@yahoo.com
  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 16, No. 5, May 2010  829 
Figure. Rates of Clostridium difﬁ  cile infection for hospital 1 (A) and 
hospital 2 (B). Arrows indicate the timing of the formulary changes 
in ﬂ  uoroquinolone antimicrobial drugs.
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